Search Results - "Rinella, Mary"

Nonalcoholic Fatty Liver Disease: A Systematic Review by Rinella, Mary E

“…IMPORTANCE: Nonalcoholic fatty liver disease and its subtype nonalcoholic steatohepatitis affect approximately 30% and 5%, respectively, of the US population…”
Get full text

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease by Cotter, Thomas G., Rinella, Mary

“…Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the United States, NAFLD and its subtype,…”
Get full text

The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health by Rinella, Mary, Charlton, Michael

Get full text

Pegozafermin for NASH — A Sprint to Start a Marathon by Rinella, Mary E.

“…Pharmacotherapy in patients with nonalcoholic steatohepatitis (NASH) has been a frustrating endeavor, with failures outnumbering successes by some margin, even…”
Get full text

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease by Rinella, Mary E, Neuschwander-Tetri, Brent A, Siddiqui, Mohammad Shadab, Abdelmalek, Manal F, Caldwell, Stephen, Barb, Diana, Kleiner, David E, Loomba, Rohit

Get full text

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease by Rinella, Mary E, Sookoian, Silvia

Get full text

Management of NAFLD: a stage-based approach by Rinella, Mary E., Sanyal, Arun J.

“…Key Points NAFLD is the most common cause of liver disease, affecting 30% of the US population; however, the goals of treatment differ based on stage of…”
Get full text

From NAFLD to MAFLD: Implications of a Premature Change in Terminology by Younossi, Zobair M., Rinella, Mary E., Sanyal, Arun J., Harrison, Stephen A., Brunt, Elizabeth M., Goodman, Zachary, Cohen, David E., Loomba, Rohit

“…Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology…”
Get full text

Mechanisms of NAFLD development and therapeutic strategies by Friedman, Scott L., Neuschwander-Tetri, Brent A., Rinella, Mary, Sanyal, Arun J.

“…There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome…”
Get full text

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis by Harrison, Stephen A., Bedossa, Pierre, Guy, Cynthia D., Schattenberg, Jörn M., Loomba, Rohit, Taub, Rebecca, Labriola, Dominic, Moussa, Sam E., Neff, Guy W., Rinella, Mary E., Anstee, Quentin M., Abdelmalek, Manal F., Younossi, Zobair, Baum, Seth J., Francque, Sven, Charlton, Michael R., Newsome, Philip N., Lanthier, Nicolas, Schiefke, Ingolf, Mangia, Alessandra, Pericàs, Juan M., Patil, Rashmee, Sanyal, Arun J., Noureddin, Mazen, Bansal, Meena B., Alkhouri, Naim, Castera, Laurent, Rudraraju, Madhavi, Ratziu, Vlad

“…Resmetirom is a selective agonist of THR-β. In adults with nonalcoholic steatohepatitis and fibrosis, daily resmetirom (80 mg or 100 mg) was superior to…”
Get full text

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction by Krag, Aleksander, Rinella, Mary E.

“…Steatotic liver disease is part of a revised nomenclature to replace the term fatty liver disease, but this should also drive forward innovation in research,…”
Get full text

Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma by Noureddin, Mazen, MD, Rinella, Mary E., MD

“…Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC). NAFLD is the…”
Get full text

Pioneering the path to NASH biomarker approval by Krag, Aleksander, Rinella, Mary E.

“…Despite an urgent need, approved and clinically usable biomarkers for non-alcoholic steatohepatitis (NASH) remain elusive — but a new study moves the field…”
Get full text

STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus by Rinella, Mary E., Noureddin, Mazen

Get full text

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases by Chalasani, Naga, Younossi, Zobair, Lavine, Joel E., Charlton, Michael, Cusi, Kenneth, Rinella, Mary, Harrison, Stephen A., Brunt, Elizabeth M., Sanyal, Arun J.

Get full text

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) by Cusi, Kenneth, Isaacs, Scott, Barb, Diana, Basu, Rita, Caprio, Sonia, Garvey, W Timothy, Kashyap, Sangeeta, Mechanick, Jeffrey I, Mouzaki, Marialena, Nadolsky, Karl, Rinella, Mary E, Vos, Miriam B, Younossi, Zobair

“…To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis…”
Get more information

Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease by Kanwal, Fasiha, Neuschwander-Tetri, Brent A, Loomba, Rohit, Rinella, Mary E

“…This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases…”
Get full text

Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases by Stine, Jonathan G., Wentworth, Brian J., Zimmet, Alex, Rinella, Mary E., Loomba, Rohit, Caldwell, Stephen H., Argo, Curtis K.

“…Summary Background Given the lack of long‐term prospective studies, it is challenging for clinicians to make informed decisions about screening and treatment…”
Get full text

Fatty Liver Disease: Diagnosis and Stratification by Saiman, Yedidya, Duarte-Rojo, Andres, Rinella, Mary E

“…Nonalcoholic fatty liver disease (NAFLD) is a major public health crisis affecting approximately 25% of the world's population. The spectrum of NAFLD ranges…”
Get full text

A multisociety Delphi consensus statement on new fatty liver disease nomenclature by Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N

“…The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This…”
Get full text